HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society (HRS), being held in San Diego this weekend. The therapy has made a major ...

Catheter-based pulmonary vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation, which delivers microsecond high-voltage electrical fields, may limit damage ...

In April, we reported on a study that raised alarms for safety issues with pulsed field ablation for atrial fibrillation. In this report, we follow up on subsequent developments for this technology.

With the recent approvals of two pulsed-field ablation (PFA) systems, US physicians now have additional options for treating their patients with atrial fibrillation (AF). Even those who are balking at ...

SAN DIEGO — Building on the success of a growing number of devices employing pulsed field ablation to control treatment-resistant paroxysmal atrial fibrillation (AF), a new spherical device produced ...

The Company’s nsPFA™ System demonstrates the ability to provide cardiac ablation and mapping capabilities with a single catheter in preclinical studies The Company collaborated with CardioNXT to ...